2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Vaccines, Non-Biological Therapies, Pharmacology, Adverse Events, Artificial Intelligence (AI), Biological Processes, Apoptosis, Metabolism, Clinical Practice (Health Services and Quality), Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Health Outcomes Research, Study Population, Human, Adult, Elderly
PAPER

5159 Phase 1/2 study of DFP-10917 in combination with venetoclax in patients with relapsed or refractory acute myeloid leukemia

Michael Keng, MD, Kiran Naqvi2, Timothy Pardee, MD, PhD3, Diego Adrianzen Herrara, MD MS4, Kenzo Iizuka, PhD5, Chun Zhang6, Barry Anderson, MD, PhD7
1 University of Virginia, Charlottesville, Virginia, United States
2 University of California Irvine, Irvine, California, United States
3 Wake Forest University, Winston-Salem, North Carolina, United States
4 University of Vermont, Burlington, Vermont, United States
5 Delta Fly Pharma, Tokushima, Japan
6 Delta Fly Pharma, Tokushima, Japan
7 Theradex Oncology, Princeton, New Jersey, United States

Background: Relapsed/refractory acute myeloid leukemia (R/R AML) remains associated with poor outcomes despite therapeutic advances. DFP-10917 is a nucleoside analog that induces DNA strand breaks after prolonged exposure and has demonstrated antileukemic activity in AML, including TP53-mutant disease. Preclinical studies suggest synergy with venetoclax. We report preliminary safety, efficacy, and pharmacokinetic (PK) results from a phase 1/2 study of DFP-10917 plus venetoclax in patients with R/R AML.

Methods: This multicenter, open-label, phase 1/2 dose-exploration and expansion study enrolled adults with R/R AML after up to 2 prior induction regimens, including venetoclax. At dose level 1, DFP-10917 4 mg/m²/day was administered by continuous intravenous infusion on Days 1-14 of each 28-day cycle, with venetoclax ramp-up to 400 mg once daily on Days 1-14. Phase 1 used a 3+3 design to evaluate dose-limiting toxicities (DLTs), adverse events, and the recommended phase 2 dose (RP2D). Phase 2 used Simon's two-stage minimax design. Overall response rate (ORR) included complete remission (CR), CR with incomplete hematologic recovery (CRi), morphologic leukemia-free state (MLFS), and partial remission (PR). If ≥3 of 10 responded in P2-stage 1, then an additional 7 pts were enrolled in P2-stage 2; ≥9 responses among 17 patients warranted further study.

Results: From September 2024 to December 2025, 30 patients were enrolled; median age was 70 years (range, 39-82), 23 (76.7%) were aged >65 years, and 21 (70.0%) were male. In phase 1, 7 patients received dose level 1; 1 withdrew consent during cycle 1 and was replaced. No DLTs occurred, and 3 responses were observed (ORR, 50.0%; 1 CR, 2 MLFS). Following Data Monitoring Committee (DMC) review, dose level -1 (DFP-10917 on Days 1-14; venetoclax on Days 1-10) was selected for expansion; dose level -2 (both agents on Days 1-10) was permitted for prolonged marrow recovery. In phase 2, 12 patients were treated in stage 1, and 2 were replaced after unrelated adverse events before response assessment. After 3 responses, the study proceeded to stage 2, in which 10 patients were treated and 3 were replaced. Among 17 evaluable patients, ORR was 52.9% (1 CR, 2 CRi, 3 MLFS, 3 PR); the DMC deemed dose level -1 safe and tolerable and recommended it for future studies. Overall, 28 patients were treated for a median of 2 cycles (range, 1-7); 20 (71.4%) had dose modifications, mainly venetoclax dose or duration adjustments for concomitant medications or tolerability. Treatment-related adverse events (TRAEs) occurred in 23 (82.1%) patients, including Grade ≥3 TRAEs in 20 (71.4%) and serious TRAEs in 2 (7.1%). The most common TRAEs were febrile neutropenia (32.1%); neutropenia and nausea (28.6% each); anemia, fatigue, and leukopenia (25.0% each); and diarrhea, thrombocytopenia, and stomatitis (21.4% each). The most common Grade ≥3 TRAEs were febrile neutropenia (32.1%), neutropenia (28.6%), leukopenia (25.0%), anemia (21.4%), thrombocytopenia, and sepsis (17.9% each). Among 23 efficacy-evaluable patients, 2 (8.7%) achieved CR, 2 (8.7%) CRi, 5 (21.7%) MLFS, and 4 (17.4%) PR, yielding a protocol-defined ORR of 56.5%. Best post-baseline aspirate and biopsy blasts were <5% in 11/23 and 8/20 patients, respectively. Two of 4 patients with CR/CRi were measurable residual disease-negative, and 4 proceeded to allogeneic hematopoietic stem cell transplantation (HSCT). At data cutoff, 3 patients remained on treatment, 18 treated patients (64.3%) had died, and 10 remained in survival follow-up. Preliminary PK analyses showed quantifiable plasma concentrations of DFP-10917 and its metabolite, CNDAU, consistent with sustained systemic exposure during infusion. Venetoclax concentrations were generally higher on Day 8 after ramp-up and repeated administration, with substantial interpatient variability.

Conclusions: DFP-10917 plus venetoclax demonstrated a manageable safety profile, no new safety signals, and preliminary antileukemic activity in a heavily pretreated R/R AML population, 80% of whom had prior venetoclax exposure. The protocol-defined ORR was 56.5%, with substantial bone marrow blast reductions, and 4 patients proceeded to allogeneic HSCT. These preliminary findings support continued evaluation of DFP-10917 plus venetoclax in R/R AML. ClinicalTrials.gov identifier: NCT06382168.

Michael Keng, MD: No relevant conflicts of interest to declare.